Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
Font Down Font Up

 
Schering-Plough K.K., Japan Gets Marketing Approval For Antidepressant Remeron - Update
7/9/2009 6:53 PM  ET

RELATED NEWS
Schering-Plough Reports Positive Interim Results From Ongoing Phase IIa Study Of Narlaprevir - Quick Facts
Schering-Plough's Grass Pollen Allergy Drug Meets Primary Endpoint - Update
Schering-Plough Says Investigational Sublingual Grass AIT Meets Primary Endpoint In Study Of Adult Subjects With History Of Grass Pollen Allergies
FDA Issues Schering-Plough Complete Response Letter For Pegintron New Use - Update
Schering-Plough Receives Complete Response Letter Regarding PEGINTRON For Malignant Melanoma - Quick Facts
TOP MARKET NEWS
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary
Stocks Posting Moderate Losses In Early Afternoon Trading - U.S. Commentary
New Guidelines Recommend Women Wait Until 21 For Cervical Cancer Screening
Stocks Seeing Further Downside In Late Morning Trading - U.S. Commentary
(RTTNews) -  Schering-Plough Corp. (SGP: News ), Thursday said its operation in Japan, Schering-Plough K.K has been granted marketing approval for Remeron or Reflex 15 mg tablets or mirtazapine indicated for the treatment of major depressive disorder.

The company indicated Remeron as a noradrenergic and serotonergic antidepressant, with a different mechanism of action compared to that of selective serotonin reuptake inhibitors or SSRI and serotonin-noradrenaline reuptake inhibitors or SNRI.

Schering-Plough developed Remeron for Japan together with the Japan-based pharmaceutical company, Meiji Seika Kabushiki Kaisha , Ltd. The product would be marketed with the trade names Remeron and Reflex.

In United States, RemeronSolTab is indicated for the treatment of major depressive disorder or MDD in adults, however, is not approved for use in pediatric patients, including children and teenagers as studies have proved antidepressants to likely increase suicidal tendency in children, adolescents, and young adults.

Short-term studies, however, have not indicated the risk of suicidality with antidepressants compared to that of placebo in adults above 24 years of age , and the risk with anti-depressants compared to placebo is also lower in adults aged 65 and older, Schering-Plough noted.
The company stated that two out of 2796 patients, who attended the premarketing clinical trials developed agranulocytosis, an acute condition involving a severe and dangerous leukopenia, while a third patient developed severe neutropenia, a hematological disorder characterized by an abnormal drop in number of a type of white blood cell called a neutrophil. However, all of the patients recovered after discontinuation of therapy.

The company said the treatment with RemeronSolTab should be discontinued, while patients develop ailments such as sore throat, fever, stomatitis or other signs of infection, along with a drop in WBC count. The patients should also be closely monitored. RemeronSolTab is also not recommended in combination with a monamine oxidase inhibitor or MAOI, or within 14 days of initiating or discontinuing therapy with an MAOI.

A six-week US controlled clinical trials indicated adverse events related to Remeron, such as somnolence, increased appetite , weight gain , and dizziness. In short-term clinical trials, 10.4% of patients discontinued therapy due to somnolence, while in a pool of pre marketing US studies 8% of patients discontinued therapy due to weight gain.

To receive FREE breaking news email alerts for Schering-Plough Corp. and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print        

     
  Trading Center
 

More Breaking News-US

128  Italian Police Arrest Two Pakistanis Linked To Mumbai Attacks
127  Indian Appointed To Key IMF Post
126  FDA Approves Bristol-Myers' Abilify To Treat Irritabilty In Pediatric Patients With Autistic Disorder - Update
125  EU Extends Review Deadline For Oracle's Proposed Takeover Of Sun Micro - Update
124  Pfizer's Geodon Approved As Adjunctive For Bipolar Disorder - Update
123  CF Nominees Enter Terra's Board - Update
122  Archipelago Learning Prices IPO Within Expected Range; Stock Soars - Update
121  Brown University And IBM Launch Multimillion-Dollar Supercomputer - Update
120  GLG Life Tech Starts Trading On Nasdaq; Shares Down 13.7% - Update
119  Global Defense Technology Prices IPO At $13/Share, Below Prior Estimate - Update
118  Dendreon Gets FDA Acceptance For Prostrate Cancer Drug Application - Update
117  Covidien's Pain Drug NDA Review Extended By FDA - Update
116  Inovio's Pre-clinincal Study Of Universal Flu Vaccines Reports Protective Response Against Multiple Influenza Strains; Stock Up - Update
115  Cloud Peak Energy Prices IPO At $15/shr - Update
114  Met-Pro Q3 Profit Plunges - Update
  

 

Copyright © 2009 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service | How To Use RTTNews.com| Advertise| Buy Content | RSS